N/A

Loading page data
Please wait a moment
Second Floor, 150 Fleet Street,
London, EC4A 2DQ.
+44 203-837-5656
108 W 39th Street, Ste 1006,
PMB2219, New York, NY 10018
+1 646-878-6329
IT Unit No. 504, 5th Floor, Icon
Tower, Baner, Pune - 411045.
+91 906 779 3500





The second major cause of death in U.S. is Cancer after cardiovascular diseases and is expected to ascend becoming the leading cause of death in next few years. According to Center for Disease Control and Prevention (CDC), malignant neoplasms accounted for 15% of deaths worldwide in 2012 with 19.3 Mn new cases of cancer are expected to be diagnosed by 2025.
The increasing number is a major challenge to physicians and researchers to fulfill the unmet needs in treatment of malignant neoplasms. Anti-neoplastic agents are used prominently as a first line therapy for alternative cancer treatment as well as in combination with surgery or radiation therapy.
Plenty of anti-neoplastic agents are available commercially for the treatment of different types of cancers including Oncotrex, Gleevec, Neosar, Cytarine, Leukeran etc. Several new anti-neoplastic agents are in clinical trials such as Oncofetal Ag (phase 1), Panobinostat (Phase 2), Volasertib (phase 2), Bortezomib (phase 4) etc. which are expected to launch in next 5-10 years.
Factors such as growing incidence of cancer across the globe and demand for cost-effective treatment options are believed to play crucial role for the growth of global anti-neoplastic agents market.
Rapid innovation in the field of personalized medicine presents a huge opportunity to manufacturers of anti-neoplastic agents. However, heterogeneous nature of cancer and high development cost of neoplastic agents are the factors limiting the growth of global anti-neoplastic agents market.